Status:
COMPLETED
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
American Heart Association
VA Pittsburgh Healthcare System
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery dise...
Detailed Description
We propose to study the effects of EPA (2 g of EPA in 4 x 500 mg capsules daily) compared to placebo supplementation in clinically-stable schizophrenic patients being treated with statins (n=30 each) ...
Eligibility Criteria
Inclusion
- Patients meeting Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria for schizophrenia (or schizoaffective disorder), major depression, or bipolar (depressed phase) disorder who are treated with antipsychotic, antidepressant or antimanic drugs and a lipid-lowering drug (statin) for 2 months or longer will be screened to participate in the proposed project.
- Based upon the CAD risk determinants (see below) and the National Cholesterol Education Program (NCEP) recommendation of goals for LDL-lowering therapy, the investigators will only enroll schizophrenic patients with baseline (before statin treatment) LDL-cholesterol exceeding:
- 70 mg/dL having CAD and CAD risk equivalents, e.g., peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease, and diabetes, as well as multiple risk factors that confer a 10-year risk for CAD \> 20%
- 130 mg/dL having 2 or more risk factors; and
- 160 mg/dL having less than 2 risk factors to participate in the EPA trial.
- In addition, these CAD-risk patients have not reached the NCEP goal level within the past year following statin treatment.
- Risk factors for CAD. The NCEP Expert Panel (NIH Publication No. 01-3670, May 2001) on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III or ATPIII) recognizes the following CAD risk factors:
- being male, 45 years or older, or being female 55 years or older;
- family history of premature CAD;
- current cigarette smoking;
- hypertension with 140/90 mmHg or greater; and
- low HDL-cholesterol (less than 40 mg/dL).
Exclusion
- Patients with history of bleeding disorders, current drug or alcohol abuse (within one month), neurological disorders (including head injury with loss of consciousness for greater than 10 minutes), antisocial personality disorder, borderline personality disorder, or mental retardation as indicated in medical records
- Patients who are pregnant (as determined by urine pregnancy test)
- Patients who have already achieved their NCEP goal in terms of their lipid profile (as indicated in laboratory tests) will be excluded.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00167310
Start Date
September 1 2005
End Date
December 1 2015
Last Update
April 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Pittsburgh Healthcare System (University Drive)
Pittsburgh, Pennsylvania, United States, 15240